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Pathogen and danger recognition by the inflamma-
some activates inflammatory caspases that mediate
inflammation and cell death. The cellular inhibitor of
apoptosis proteins (cIAPs) function in apoptosis
and innate immunity, but their role in modulating the
inflammasome and the inflammatory caspases is
unknown. Here we report that the cIAPs are critical
effectors of the inflammasome and are required for
efficient caspase-1 activation. cIAP1, cIAP2, and the
adaptor protein TRAF2 interacted with caspase-1-
containing complexes and mediated the activating
nondegradativeK63-linkedpolyubiquitinationof cas-
pase-1. Deficiency in cIAP1 (encoded by Birc2) or
cIAP2 (Birc3) impaired caspase-1 activation after
spontaneous or agonist-induced inflammasome
assembly, and Birc2/ or Birc3/ mice or mice
administeredwith an IAPantagonist had adampened
response to inflammasome agonists and were resis-
tant to peritonitis. Our results describe a role for the
cIAPs in innate immunity and further demonstrate
the evolutionary conservation between cell death
and inflammation mechanisms.
INTRODUCTION
The innate immune system is critical for host defense against
invading microorganisms and the repair of damaged tissue. One
of its most primitive responses is the elimination of compromised
cells by programmed cell death, a response found in all metazoan
phyla (Zitvogel and Kroemer, 2008). Among the innate immunity
effectors are evolutionarily conserved germline-encoded pattern
recognition receptors (PRRs) that recognize specific microbial
motifs or endogenousdanger signals (microbe-or danger-associ-
ated molecular patterns [MAMPs or DAMPs]). PRRs include,
among others, trans-membrane Toll-like receptors (TLRs) and
cytosolic nucleotide-bindingdomainand leucine-rich repeat-con-
taining proteins (NLRs) which, when engaged, trigger inflamma-
tion and, in some contexts, cell death (Kumagai and Akira, 2010).IIt is becoming increasingly appreciated that the pathways that
initiateand regulate inflammationand innate immunityarecoupled
to the cell death machinery. For instance, caspases mediate key
events in both types of responses and theirmechanismsof activa-
tion are strikingly conserved (Yeretssian et al., 2008).
Caspase-1 plays a paramount role in inflammatory and infec-
tious diseases. Active caspase-1 converts pro-interleukin-1b
(pro-IL-1b) and pro-IL-18 into their mature cytokine forms and
targets a number of other cellular proteins to amplify the inflam-
matory response and inducepyroptosis (Shao et al., 2007; Labbe´
and Saleh, 2008). Consistently, caspase-1-deficient animals are
susceptible to infections because of impaired inflammation and
pyroptosis (McIntire et al., 2009) and are more sensitive to the
induction of colitis and colitis-associated colorectal cancer
because of an inherent defect in tissue repair (Allen et al., 2010;
Dupaul-Chicoine et al., 2010; Zaki et al., 2010). In contrast,
lack of caspase-1 activity is protective in diseases of excessive
inflammation such as septic shock (Li et al., 1995).
A number of inflammasomes have been identified including
complexes scaffolded by NLRP proteins, NAIP receptors in
conjunction with NLRC4, RIG-I, and AIM2. These platforms
recruit caspase-1 directly or through the adaptor protein ASC
(Kofoed and Vance, 2011; Schroder and Tschopp, 2010; Zhao
et al., 2011). With the exception of NLRP3 that is stimulated by
a variety of disparate signals, the inflammasomes have defined
agonists and primarily play a role in the detection of pathogens.
However, the molecular events leading to efficient caspase-1
activation and regulation are unknown.
The inhibitors of apoptosis proteins (IAPs) are critical regula-
tors of cell death and inflammation (Lopez and Meier, 2010;
O’Riordan et al., 2008). XIAP, cIAP1, and cIAP2 consist of
three N-terminal baculovirus IAP repeat (BIR) domains and a
C-terminal RING domain that confers E3 ubiquitin ligase activity
(Lorick et al., 1999). cIAP1 and cIAP2 also contain a central
caspase-recruitment domain (CARD) involved in autoinhibition
of their E3 ligase activity (Lopez et al., 2011). Insights into the
function of cIAP1 and cIAP2 came with the development of
synthetic IAP antagonists based on the structure of SMAC
(second mitochondrial activator of caspases), an endogenous
IAP inhibitor sequestered to the mitochondria but released
after mitochondrial outer membrane permeabilization (MOMP).
It has been shown that these SMAC mimetics (SM) selectivelymmunity 35, 897–907, December 23, 2011 ª2011 Elsevier Inc. 897
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Figure 1. The cIAPs Are Required for Inflammsome Assembly and Caspase-1 Activation
(A) The cytosolic fractions of LPS-stimulated THP-1 cells were immunodepleted with cIAP2 antibodies and inflammasome assembly was induced by heating
the supernatants to 30C for the indicated time points. Caspase-1 cleavage and IL-1b processing were detected by immunoblot.
(B) The cytosolic fractions of LPS-stimulated THP-1 cells that were pretreated for 1 hr with BV6 or DMSO were heated at 30C for the indicated time points.
(C) The cytosolic fractions of LPS-stimulated primary BMDM from wild-type (WT), Birc3/, or Casp1/ mice were heated at 30C for the indicated time
points.
(D) Cleavage of the caspase-1-selective substrate Ac-WEHD-AFC by lysates from HEK293T cells transfected with caspase-1 together with a vector control or
increasing concentrations of cIAP2 (left) or cIAP1 (right).
(E) Propidium-iodide staining of HEK293T cells expressing caspase-1 or caspase-9with a vector control, cIAP2, or XIAP.Where indicated, cells were treated with
the caspase-1 inhibitor YVAD-FMK (50 mM).
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cIAP1 and cIAP2 Promote Caspase-1 Activityinteract with cIAP1 and cIAP2 to rapidly induce their
autoubiquitination and proteasomal degradation (Petersen
et al., 2007; Varfolomeev et al., 2007; Vince et al., 2007). Use
of SM on cancer cell lines revealed that cIAP1 and cIAP2 were
responsible for K63-linked polyubiquitination of receptor inter-
acting protein 1 (RIP1) downstream of TNFR1, promoting
NF-kB activation and prosurvival signaling, while suppressing
apoptosis (Bertrand et al., 2008). cIAP1 and cIAP2 also direct
the degradative (K48-linked) ubiquitination of NF-kB-inducing
kinase (NIK) to maintain the noncanonical NF-kB pathway in
check (Varfolomeev et al., 2007; Vince et al., 2007). Degradation
of cIAP1 and cIAP2 by SM thus results in spontaneous activation
of this pathway and overproduction of TNF-a, which induces
apoptosis in an autocrine loop.
In addition to promoting cell survival, the IAPs exert important
roles in inflammation and innate immunity. Indeed, cIAP2-
deficient mice have reduced cytokine amounts in response to
LPS and are resistant to LPS endotoxemia (Conte et al., 2006).
Furthermore, Xiap/ mice have an impaired innate immune
control of Listeria monocytogenes infection (Bauler et al.,
2008). We have recently identified cIAP1 and cIAP2 as important
effectors of innate immunity, mediating critical steps in NOD
signaling (Bertrand et al., 2009). Moreover, cIAP1 and cIAP2
were shown to mediate MAPK activation downstream of TLR4
signaling by catalyzing degradative K48-linked ubiquitination of
TRAF3 (Tseng et al., 2010).
Although cIAP1 and cIAP2 have been implicated in key
processes regulating apoptotic caspases and innate immunity,
their roles in modulating the inflammatory caspases and inflam-
masome pathway are unclear. Here we report a function of
cIAP1 and cIAP2 in stimulating caspase-1 activation and inflam-
masome-dependent innate immunity signaling. cIAP1 and
cIAP2 interacted with caspase-1 through their respective N
termini in complexes containing TRAF2 and directed nondegra-
dative K63-linked polyubiquitination of caspase-1. We showed
that depletion of cIAP1 or cIAP2 or deletion of Birc2 (encoding
cIAP1) orBirc3 (encoding cIAP2)markedly suppressed inflamma-
some activation.Macrophages fromBirc3/micewere deficient
in caspase-1 activation and subsequent production of IL-1b in
response to various inflammasomeagonists. In addition,Birc2/
or Birc3/ mice, or wild-type animals treated with SM, had
dampened neutrophil infiltration and cytokine production
in response to exposure to inflammasome stimuli. Thus, our
resultsdefinea role of cIAP1andcIAP2 in inflammationand innate
immunity through the molecular regulation of the inflammasome.
RESULTS
cIAP1 and cIAP2 Are Required for Inflammasome
Assembly and Caspase-1 Activation
We initially investigated whether cIAP1 and cIAP2 are important
for caspase-1 activation, by using an established cell-free(F) Cleavage of Ac-WEHD-AFC by lysates of HEK293T cells transfected with siRN
caspase-1. Top panels show cIAP1 and TRAF2 expression levels as detected b
(G) Cleavage of in-vitro-transcribed and -translated IL-1b by HEK293T lysates f
pendent times with similar results.
Cell-based studies were performed at least three independent times with compa
Student’s t test was used for statistical analysis: *p < 0.05; **p < 0.1.
Isystem in which the inflammasome is spontaneously activated
(Martinon et al., 2002). This approach allowed us to study the
role of the cIAPs in the absence of any external agonists, overex-
pression systems, or cell death signals. As expected, incubation
of lysates from differentiated THP-1 monocytes at 30C resulted
in rapid inflammasome formation and caspase-1 activation, as
determined by the appearance of the p20 subunit of the active
enzyme and the concurrent processing of pro-IL-1b into its
mature p17 fragment (Figure 1A). Immunodepletion of cIAP2
(Figure 1A) or treatment of cells with the SM BV6, which rapidly
triggers the degradation of both cIAP1 and cIAP2 but inefficiently
depletes XIAP (Figure 1B, top; Varfolomeev et al., 2007), mark-
edly inhibited caspase-1 activation and IL-1b processing
(Figures 1A and 1B, bottom). To rule out any indirect effects of
acute cIAP depletion, we examined spontaneous inflammasome
activation in lysates of bone marrow-derived macrophages
(BMDM) isolated from wild-type, Casp1/, or Birc3/ mice.
Activation of caspase-1 and production of mature IL-1b were
observed within 15 min of inflammasome stimulation in wild-
type cell lysates, but were markedly dampened in lysates from
Birc3/ cells (Figure 1C). Consistent with these findings, over-
expression of cIAP1 or cIAP2 in HEK293T cells markedly
enhanced caspase-1 catalysis (Figure 1D) and caspase-1-
dependent cell death (Figure 1E). This stimulatory function on
caspase-1 was not shared by caspase-9, an apoptosis initiator
caspase, and was specific to cIAP1 and cIAP2, as shown
by the fact that expression of another IAP family member,
XIAP, had no effect on caspase-1-mediated cell death (Fig-
ure 1E). Concordantly, siRNA-mediated depletion of endoge-
nous cIAP1 or cIAP2, alone or in combination, dramatically
blunted caspase-1 activity toward its selective fluorogenic
tetrapeptide substrate WEHD-AFC (Figure 1F) or its natural
substrate pro-IL-1b (Figure 1G). Depletion of TRAF2, an adaptor
protein constitutively associated with the cIAPs (Rothe et al.,
1995; Shu et al., 1996), also inhibited caspase-1 enzymatic
activity (Figures 1F and 1G), suggesting that the cIAPs in associ-
ation with TRAF2 exert important regulatory activity on caspase-
1 activation within the inflammasome.
The cIAPs Physically Interact with Caspase-1
Our results indicating a critical role of the cIAPs in inflamma-
some activation suggested that cIAP1 and cIAP2 probably func-
tioned at the level of caspase-1. To explore this hypothesis, we
performed coimmunoprecipitation experiments in HEK293T
cells expressing caspase-1 with or without cIAP1, cIAP2, or
TRAF2. Figure 2A and Figure S1 (available online) show that
cIAP1, cIAP2, and TRAF2 coimmunoprecipitated with full-length
caspase-1-containing complexes. To map the domains medi-
ating this interaction, we generated deletion mutants and exam-
ined their association by coimmunprecipitation. Deletion of the
caspase-1 CARD inhibited its interaction with cIAP2-containing
complexes, whereas a CARD-only protein was capable ofAs targeting cIAP1, cIAP2, TRAF2, or GFP and subsequently transfected with
y immunoblot.
rom cells treated as in (F). Cell-free assays were performed one to two inde-
rable results. AFU, arbitrary fluorescence units. Data represent mean ± SEM.
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Figure 2. cIAP1, cIAP2, and TRAF2 Associate with Caspase-1-Containing Complexes
(A) HEK293T cells were transfected with Myc-cIAP2 or TRAF2 along with control vector or Flag-caspase-1. Caspase-1 was immunoprecipitated with M2-
sepharose beads and coimmunoprecipitated cIAP2 and TRAF2 detected by immunoblotting as indicated.
(B) HEK293T cells were transfected with Myc-cIAP2 along with Flag-caspase-1 or a Flag-tagged caspase-1 deletion mutants. Caspase-1 was immunopre-
cipitated with M2-sepharose beads and coimmunoprecipitated cIAP2 detected by immunoblotting as indicated.
(C) HEK293T cells were transfected with HA-cIAP2 or a HA-tagged cIAP2 deletion mutants along with Flag-caspase-1. Caspase-1 was immunoprecipitated with
M2-sepharose beads and coimmunoprecipitated cIAP2 detected by immunoblotting as indicated.
(D) In-vitro-transcribed and -translated caspase-1 labeled with 35S-methionine (Input) was incubated overnight with bacterially produced GST, GST-cIAP1, or
GST-cIAP2 bound to Sepharose beads (Pull down). Caspase-1 binding was revealed by autoradiography.
(E) THP-1 cells were stimulated with LPS (1 mg/ml) for 24 hr and endogenous caspase-1 immunoprecipitated with caspase-1 antibodies. cIAP2 coimmuno-
precipitation was revealed by immunoblotting as indicated.
(F) THP-1 cells were stimulatedwith LPS (1 mg/ml) for different time points and endogenous caspase-1 immunoprecipitatedwith caspase-1 antibodies. cIAP1 and
cIAP2 coimmunoprecipitation was revealed by immunoblotting as indicated.
All coimmunprecipitation experiments were performed independently two to three times with comparable results.
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cIAP1 and cIAP2 Promote Caspase-1 Activitybinding to these complexes (Figure 2B). Although CARD
domains mediate homotypic interactions, the cIAP2 CARD
was not required for its association with caspase-1 (Figure 2C).
Rather, the N-terminal BIR1 domain of cIAP2 was necessary
and sufficient for its interaction with caspase-1 (Figure 2C). To
validate the association between caspase-1 and the cIAPs,
we conducted in vitro pull-down experiments. Purified recombi-
nant GST-cIAP1 or GST-cIAP2 fusion proteins, but not a GST
control protein, specifically bound to 35S-methionine-labeled
in-vitro-transcribed and translated caspase-1 (Figure 2D).
Furthermore, cIAP1 and cIAP2 interacted with caspase-1 at
the endogenous level (Figures 2E and 2F). This was examined
in LPS-stimulated THP-1 cells, because resting cellular
amounts of cIAP2 are relatively low and expression is highly
inducible by NF-kB (Wang et al., 1998). Indeed, cIAP2 was
not detected in whole cell extracts of untreated cells, whereas
it was strongly upregulated after LPS treatment and was found900 Immunity 35, 897–907, December 23, 2011 ª2011 Elsevier Inc.to coimmunoprecipitate with caspase-1 (Figures 2E and 2F).
Altogether these results indicate an association of cIAP1,
cIAP2, and TRAF2 with caspase-1-containing complexes and
the requirement for these proteins for caspase-1 catalysis within
the inflammasome.
The cIAP E3 Ligase Activity Mediates K63-Linked
Polyubiquitination of Caspase-1
XIAP, cIAP1, and cIAP2 have all been reported to mono- or poly-
ubiquitinate caspase-3, caspase-7, and caspase-9 (Choi et al.,
2009; Huang et al., 2000; Morizane et al., 2005; Suzuki et al.,
2001). To test whether the cIAPs could mediate caspase-1 ubiq-
uitination, we expressed caspase-1, HA-ubiquitin, and cIAP2
in HEK293T cells, immunoprecipitated caspase-1 under highly
stringent conditions, and probed for ubiquitin by immunoblot.
At baseline, caspase-1 was weakly polyubiquitinated (Figure 3A,
lane 2) but became markedly polyubiquitinated when cIAP2
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Figure 3. cIAPs Direct K63-Linked Polyubiquitination of Caspase-1
(A) HEK293T cells were transfected with HA-ubiquitin and Flag-caspase-1 along with Myc-cIAP2 or E3 inactive Myc-cIAP2*.
(B) HEK293T cells were transfected with siRNAs targeting cIAP1 and cIAP2 or GFP and subsequently transfected with Flag-caspase-1 and HA-ubiquitin.
(A and B) Caspase-1 was immunoprecipitated in high-stringency buffer and ubiquitinated caspase-1 detected by immunoblotting with HA antibodies.
(C) HEK293T cells were transfected with HA-ubiquitin and a Flag-tagged CARD-deletion caspase-1 mutant (DCARD-F) along with a Myc-cIAP2 or E3 inactive
Myc-cIAP2*. Caspase-1-DCARD was immunoprecipitated in high-stringency buffer and ubiquitination detected by immunoblotting with HA antibodies.
(D) HEK293T cells were transfectedwith HA-ubiquitin and Flag-tagged CARD-only caspase-1mutant (CARD-F) alongwithMyc-cIAP2 or E3 inactiveMyc-cIAP2*.
CARD-caspase-1 was immunoprecipitated in high-stringency buffer and ubiquitination detected by immunoblotting with HA antibodies.
(E) HEK293T cells were transfected with HA-tagged K48-only or K63-only ubiquitin in combination with Flag-caspase-1 and Myc-cIAP2 or E3 inactive Myc-
cIAP2*. Caspase-1 was immunoprecipitated in high-stringency buffer and ubiquitination detected by immunoblotting with HA antibodies.
(F) BMDM fromWT, Birc3/, or Casp1/mice were primed with LPS (1 mg/ml for 4 hr) before treatment with ATP (5 mM). Cells were lysed in denaturing buffer,
endogenous caspase-1 immunoprecipitated, and ubiquitination detected by immunobloting with antibodies against total ubiquitin or K63-specific chains.
All ubiquitination assays were performed independently two to three times with comparable results except the K63 immunoblot, which was performed once.
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Figure 4. cIAP2 Is Required for Inflammasome Function in Macro-
phages
(A) BMDM fromWT,Birc3/, orCasp1/micewere primedwith LPS (1 mg/ml
for 4 hr) before treatment with the inflammasome agonists ATP (5 mM for
40 min), MSU (100 mg/ml for 5 hr), alum (100 mg/ml for 5 hr), liposome-
encapsulated flagellin (2 mg/ml for 5 hr), or S. typhymurium (MOI 10 for 1 hr).
IL-1b secretion in the supernatant was measured by ELISA.
(B) LPS-primed BMDM lysates were examined for pro-IL-1b expression by
quantitative real-time PCR and immunoblot. ASC and NLRP3 expression were
measured by quantitative real-time PCR.
(C) Lysates of cells treated as in (A) were analyzed by immunoblot for caspase-
1 cleavage and IL-1b processing.
Inflammasome agonist assays were performed at least three independent
times with similar results. Data represent mean ± SEM. Student’s t test was
used for statistical analysis: *p < 0.05; **p < 0.1.
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cIAP1 and cIAP2 Promote Caspase-1 Activitywas expressed (Figure 3A, lane 3). Conversely, caspase-1 ubiq-
uitination was markedly reduced with depletion of endogenous
cIAP1 and cIAP2 (Figure 3B, lane 3). To determine whether the
E3 ligase activity of cIAP2 was required for caspase-1 ubiq-
uitination, we coexpressed caspase-1 with a catalytically inac-
tive mutant of cIAP2 harboring an Ala in the position of the
metal-coordination residue His574 (Cheung et al., 2008). This
E3 inactive form of cIAP2 was impaired in mediating the poly-
ubiquitination of caspase-1 (Figure 3A, lane 4). Casp-1-CARD,
but not casp-1-DCARD, showed enhanced ubiquitination when
coexpressed with cIAP2 (Figures 3C and 3D), suggesting that
caspase-1 ubiquitination occurs through its ability to interact
with cIAP2. To determine the type of ubiquitin chains catalyzed
by cIAP2, we expressed caspase-1 with mutant forms of ubiqui-
tin that can be only K48 or K63 linked and found that caspase-1
was mostly conjugated with K63-linked polyubiquitin chains
(Figure 3E). Importantly, we confirmed the ability of cIAP2 to
mediate caspase-1 polyubiquitination endogenously with wild-
type, Casp1/, and Birc3/ BMDM. Treatment with an inflam-
masome agonist resulted in caspase-1 polyubiquitination in
wild-type cells but not Birc3/ macrophages (Figure 3F).
Furthermore, probing with a linkage-specific antibody revealed
that caspase-1 was modified with K63-linked polyubiquitin
chains (Figure 3F). Together, our results show that the cIAP E3
ligase activity mediates nondegradative and signaling-associ-
ated K63-linked polyubiquitination of caspase-1.
The cIAPs Are Universal Regulators of Caspase-1
Activation
To investigate the physiological relevance of these findings, we
examined IL-1b production by BMDM fromwild-type, Casp1/,
or Birc3/ mice in response to stimulation with various inflam-
masome agonists, including ATP, monosodium urate crystals
(MSU), alum, Salmonella typhimurium, and cytosolic flagellin.
In each case, IL-1b production was significantly reduced in
Birc3/ macrophages compared to wild-type cells, indepen-
dently of an effect on pro-IL-1b or inflammasome component
transcription (Figures 4A and 4B). Furthermore, the impaired
production of mature IL-1b by Birc3/ cells directly correlated
with reduced caspase-1 activation and processing (Figure 4C).
These results indicated that the cIAPs play an essential role in
inflammasome activation, irrespective of the activating agonist
or NLR engaged. Consistently, treatment of wild-type BMDM
with SM resulted in dampened caspase-1 activation in response
to extracellular ATP (Figures S2A and S2B). Conversely, pro-
longed SM treatment stimulated the inflammasome by triggering
proinflammatory pathways that primed its activation (Figures
S2A and S2B). SM alone had no effect on inflammasome activity
(Figures S2A–S2C) but resulted inmarked caspase-1 processing
and IL-1b secretion in the presence of ATP alone (Figures S2B
and S2C). This effect was abrogated by cycloheximide treat-
ment and thus dependent on de novo protein synthesis. Immu-
noblotting analysis of pro-IL-1b levels in SM-treated macro-
phages indicated that prolonged SM exposure upregulated
pro-IL-1b to levels similar to those obtained with LPS stimulation
(Figure S2D). Importantly, genetic or SM-induced cIAP depletion
had no effect on cell survival (Figures S3A and S3B). These
results indicate that acute IAP depletion by SM treatment
prevents inflammasome activation, but prolonged exposure to902 Immunity 35, 897–907, December 23, 2011 ª2011 Elsevier Inc.
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Figure 5. Birc3–/– Mice Exhibit a Blunted Inflammasome Response
(A) WT, Birc3/, or Casp1/ mice were injected intraperitoneally with MSU
(1 mg/ml) or endotoxin-free PBS. GR-1+ cells in the peritoneal lavage were
enumerated by flow cytometry 16 hr later.
(B) WT, Birc3/, or Casp1/ mice were injected intraperitoneally with MSU
(1 mg/ml). IL-1b levels in the peritoneal lavage were quantified by ELISA 4 hr
later.
(C) WT, Birc3/, or Casp1/ mice were injected intraperitoneally with alum
(50 mg/ml) or endotoxin-free PBS. GR-1+ cells in the peritoneal lavage were
enumerated by flow cytometry 16 hr later.
(D) WT, Birc3/, or Casp1/ mice were injected intraperitoneally with alum
(2 mg/ml). IL-1b levels in the peritoneal lavage were quantified by ELISA 4 hr
later.
(E and F) WT, Birc2/, or Casp1/ mice were treated as in (C) and (D),
respectively.
(G) WT, Birc3/, or Casp1/ mice were treated as in (B). 2 hr prior to alum
treatment, animals were injected intravenously with DMSOor BV6 (1mg/kg, + ;
or 3 mg/kg, +++).
(H) WT, Birc3/, or Casp1/ mice were treated as in (A). 2 hr prior to treat-
ment, animals were injected intravenously with DMSO or BV6 (1 mg/kg, + ; or
3 mg/kg, +++).
Peritonitis experiments were performed two to three times on Birc3/ mice
and one time on Birc3/ mice. BV6 experiments were performed once. n =
3–6 mice per experiment. Data represent mean ± SEM. Student’s t test was
used for statistical analysis: *p < 0.05; **p < 0.1.
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Ithese compounds might result in an indirect secondary inflam-
masome response.
cIAP-Deficient Mice Exhibit a Blunted
Caspase-1-Dependent Inflammatory Response
To determine the contribution of the cIAPs to inflammasome-
dependent signals in vivo, we examined the response of wild-
type,Casp1/,Birc2/, orBirc3/mice to an acute peritonitis
model, whereby intraperitoneal injection of inflammasome
agonists such as alum or MSU triggers neutrophil infiltration in
an IL-1-dependent manner (Hornung et al., 2008; Martinon
et al., 2006). MSU injection led to a massive recruitment of
GR-1+ cells to the peritoneum of wild-type mice (Figure 5A),
but this response was significantly blunted in Casp1/ or
Birc3/ mice (Figure 5A). Similarly, IL-1b production was
induced in wild-type but not Casp1/ or Birc3/ mice (Fig-
ure 5B), indicating that impaired caspase-1 activation contrib-
uted to the blunted neutrophil recruitment phenotype. Similar
results were obtained with alum-induced peritonitis in both
Birc2/ and Birc3/ animals (Figures 5C–5F). Intravenous
injection of wild-type mice with SM, 2 hr prior to alum adminis-
tration, significantly reduced peritoneal GR-1+ cell recruitment
(Figure 5G) and IL-1b production (Figure 5H) to levels measured
in Casp1/ animals, further supporting the requirement of the
cIAPs in inflammasome activation in vivo. Notably, SM treatment
alone did not trigger the synthesis of pro-IL-1b (Figure 5H) or that
of other proinflammatory cytokines such as IL-6 (Figure S4).
Thus, acute administration of SM conferred protection in vivo
by repressing inflammasome signaling without any measurable
secondary proinflammatory effects.
DISCUSSION
Inflammatory caspase activation by the inflammasome contrib-
utes to innate immunity by inducing cytokine production andmmunity 35, 897–907, December 23, 2011 ª2011 Elsevier Inc. 903
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cIAP1 and cIAP2 Promote Caspase-1 Activitypyroptosis. The cIAPs are important regulators of both cell death
and inflammation but their role in inflammatory caspase function
has been unclear to date. Here, we demonstrate that cIAP1 and
cIAP2 are essential promoters of caspase-1 activity and of the
inflammasome innate immune pathway. Deficiency in either
cIAP1 or cIAP2 severely impaired caspase-1 activation, resulting
in a blunted inflammatory reaction in response to various inflam-
masome agonists. This has been demonstrated 3-fold, in a cell-
free system, in primary macrophages, and in vivo. Indeed, the
inflammatory response of Birc3/ mice to systemic inflamma-
some agonist exposure is significantly blunted and equivalent
to that of Casp1/ mice. Together, these findings indicate that
the cIAPs are integral to the inflammasome pathway.
The modalities of caspase-1 activation and regulation within
the inflammasome are not fully understood. It has been sug-
gested that caspase-1 catalysis occurs by induced proximity,
in a manner analogous to caspase-9 activation by the apopto-
some (Martinon et al., 2002), but whether additional modulators
are required to amplify this response and induce maximal cas-
pase-1 activation has not been examined. Our results indicate
that the cIAPs are recruited to caspase-1-containing complexes
and modulate their activity. We found that cIAP1 and cIAP2
physically interact with caspase-1. Binding occurs via the cas-
pase-1 CARD and the first BIR domain of the cIAP. The IAP
BIR domains are grouped according to the presence of a deep
peptide-binding groove. In type 2 BIRs (BIR2 and BIR3), this
hydrophobic cleft mediates binding to IAP-binding motif (IBM)-
containing proteins such as SMAC and caspase-3, caspase-7,
and caspase-9 (Scott et al., 2005; Srinivasula et al., 2001).
Type 1 BIRs (BIR1), on the other hand, lack this groove and
employ a different mode to interact with binding partners
including inflammatory mediators such as TNFR-associated
factors (TRAFs) or TGF-b-associated kinase binding protein
(TAB1) (Lu et al., 2007; Samuel et al., 2006). Our results indicate
that the cIAPs bind to caspase-1 through BIR1, which suggests
a distinct nature of cIAP function in inflammatory versus
apoptotic caspase regulation.
The inflammatory functions of the cIAPs are tightly associated
with adaptor proteins of the TRAF family (Bertrand et al., 2008,
2009; Mao et al., 2010; Shu et al., 1996). Because the BIR1 of
cIAP1 and cIAP2 constitutively binds the N-domain of TRAF2
as part of a preformed complex (Rothe et al., 1995; Shu et al.,
1996), we examined a possible function for TRAF2 in caspase-
1 activation. We found that TRAF2 is similarly associated with
caspase-1-containing complexes and is required for its catalytic
activity and downstream proinflammatory events.
Interestingly, the cIAP-caspase-1 interaction results in nonde-
gradative K63-linked polyubiquitination of caspase-1. Apoptotic
caspase ubiquitination by the IAPs is an evolutionarily conserved
regulatory mechanism. In D. melanogaster, DIAP1 regulation of
DRONC and drICE is dependent on polyubiquitination (Wilson
et al., 2002). In mammalian cells, XIAP-mediated inactivation of
apoptotic caspases requires a functional RING motif (Schile
et al., 2008), and IAP-dependent mono- or polyubiquitinate cas-
pase-3, caspase-7, and caspase-9 has been reported (Choi
et al., 2009; Huang et al., 2000; Morizane et al., 2005; Suzuki
et al., 2001), but the functional consequence of this modification
has not been clearly defined. The ubiquitin ligase activity of
the IAPs is also essential for their proinflammatory functions.904 Immunity 35, 897–907, December 23, 2011 ª2011 Elsevier Inc.Ubiquitination of IMD by DIAP2 permits NF-kB activation in
Drosophila (Paquette et al., 2010), and themammalian homologs
of IMD, RIP1 andRIP2, are polyubiquitinated by cIAP1 and cIAP2
to activate NF-kB and MAP kinase signaling downstream of
TNFR1 and NOD receptors, respectively (Bertrand et al., 2008,
2009). A previous study did not detect cIAP2-directed ubiq-
uitination of caspase-1 in a reconstituted in vitro assay via
recombinant E1, E2, and ubiquitin (Huang et al., 2000). Although
this may indicate a requirement for cofactors absent in this
minimal system, it is also possible that the E3 activity of the
cIAPs functions to recruit ubiquitin binding domain-containing
adaptor proteins and/or E3 ligases that are necessary for
caspase-1 ubiquitination. Dissociating these two possibilities
is a remaining challenge and a key step in understanding the
functional significance of caspase-1 ubiquitination. Modification
with nondegradative K63-linked polyubiquitin chains is an
important scaffolding mechanism in innate immunity signaling
(Bhoj and Chen, 2009). K63 ubiquitination of caspase-1 could
serve a number of functions such as the recruitment and oligo-
merization of inflammasome components, the induction of
conformational changes necessary for enhanced or sustained
caspase-1 catalytic activity, or the engagement of additional
proteins that mediate the stimulatory effects of cIAP1 and
cIAP2 on caspase-1. The nature of the factor(s) recruited to cas-
pase-1 through its polyubiquitin scaffolds is currently unknown
and will require further investigation. Interestingly, unanchored
K63 polyubiquitin chains have been recently shown to bind to
and modulate the function of proinflammatory proteins including
RIG-I (Zeng et al., 2010). Whether this is the case for caspase-1
or whether the K63 polyubiquitin chains are anchored to
a specific lysine residue within the CARD of caspase-1 will also
need to be examined.
The cIAPs are thought to be highly interdependent. They have
been shown to exist in preformed heteromeric complexes, and
changes in expression of one cIAP impact the stability of the
other (Conte et al., 2006; Rajalingam et al., 2006). Previous
studies from our group and others (Bertrand et al., 2008, 2009)
have demonstrated that cIAP1 and cIAP2 functionwithin a binary
complex and play nonredundant roles in innate immunity.
Consistently, we find that depletion of either cIAP1 or cIAP2 is
sufficient to extinguish caspase-1 activation. Furthermore,
although the role of XIAP in inflammasome function has not
been thoroughly investigated, we found that, contrary to cIAP1
and cIAP2, XIAP expression had no effect on caspase-1 catalytic
activity.
Altogether, our results identify cIAP1 and cIAP2 as critical
mediators of inflammasome function. Although minimal condi-
tions for inflammasome assembly do not include the cIAPs
(Faustin et al., 2007), their activity greatly amplifies caspase-1
catalysis and their absence severely impairs inflammasome
function under physiological conditions. Notably, pharmacolog-
ical depletion of the cIAPs by SM treatment markedly inhibited
caspase-1 activation both in vitro and in vivo. Several IAP
antagonists are currently being developed as anticancer thera-
peutics, because several cancer cell lines have been shown
to be sensitive to SM-induced apoptosis in vitro (Bertrand
et al., 2008; Petersen et al., 2007; Varfolomeev et al., 2007;
Vince et al., 2007). Our in vivo results showing that acute SM
administration inhibited the inflammasome response in an
Immunity
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peutic potential of these compounds in inflammatory diseases.
The use of SM must, however, be approached cautiously,
because prolonged in vitro exposure leads to enhanced pro-
IL-1b expression and maturation. This is possibly the result of
spontaneous NIK-dependent TNF-a overproduction, which
can serve as an efficient ‘‘priming’’ signal for the inflammasome
(Bauernfeind et al., 2009). The absence of cIAP2 at basal condi-
tions also further demonstrates the importance of the initial
‘‘priming’’ signal necessary for transcriptional upregulation of
inflammasome components including cIAP2 itself.
The identification of the cIAPs as key regulators of the inflam-
masome pathway reveals insights into the mechanistic basis of
caspase-1 activation and provides therapeutic opportunities
for the treatment of immune-mediated inflammatory diseases.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents
All cell culture supplies were from Wisent unless specified otherwise. Anti-
human IL-1b was from Cell Signaling (cat# 2022) and anti-mouse IL-1b from
R&D (cat# AF401NA). Anti-human caspase-1 p20 was obtained from Merck.
Antibodies against the mouse caspase-1 p10 subunit were purchased from
Santa Cruz (cat# sc-514) and antibodies against the p20 subunit were
obtained from Genentech. Human cIAP1- and cIAP2-specific antibodies
were purchased from R&D (cat# AF8181 and AF8171). Ubiquitin antibodies
were purchased from Santa Cruz (cat# sc-8017) and anti-K63-specific anti-
bodies from Millipore (cat# 05-1313). Anti-mouse-GR-1 with FITC tag was
purchased from BD Biosciences (cat# 553126). Monoclonal antibodies for
HA (cat# 11583816001) and Myc (cat# 11667149001) tag were from Roche.
Anti-Flag monoclonal antibody (cat# F3165), M2 agarose beads (cat#
A2220), and Flag peptide (cat# F3290) were from Sigma. Protein A (cat#
P9424) and protein G (cat# P3296) sepharose beads were from Sigma. BV6
was obtained from Genentech. siRNA targeting human cIAP1 and cIAP2
were obtained from Invitrogen. siRNA directed against human TRAF2 (cat#
J-005198-05) and GFP (cat# P-002048-01-02) were purchased from
Dharmacon. Active recombinant human caspase-1 was purchased from
BioMol (cat# SE-168). ATP was purchased from Sigma (cat# A3377), ImjectA-
lum was from Pierce (cat# PI77161), MSU was from Alexis Biochemicals
(cat# ALX-400-047), Flagellin from Invivogen (cat# TLRL-STFLA), crude LPS
from Sigma (cat# L2630), and ultra-pure LPS from Invivogen (cat# TLRL-
PELPS). Lipofectamine 2000 was purchased from Invitrogen (cat# 11668-
019) and DOTAP was from Roche (cat# 11202375001). RT-PCR reagents
were all from Invitrogen and SYBR green was purchased from BioRad
(cat# 1725852). DuoSet ELISA was purchased from R&D: anti-mouse-IL-1b
(cat# DY401), anti-mouse-IL-6 (cat# DY406). For in vitro transcription and
translation, a TNT T7 Rabbit Reticulocyte Lysate ITT kit was purchased from
Promega (cat# PRL4610). LDH release was measured with the CytoTox 96
Non-Radioactive Cytotoxicity Assay from Promega (cat# G1780).
Animal Strains
Wild-type C57BL/6 mice were either bred in-house or purchased from a local
supplier (Charles River Laboratories, St-Constant, Quebec). cIAP2- (Birc3/)
and caspase-1- (Casp1/) deficient mice were on a pure C57BL/6 back-
ground and bred in-house at the McGill University animal housing facilities.
All animal experiments were performed under guidelines of the animal ethics
committee of McGill University.
Cell-Free Inflammasome Activation Assay
Cells were stimulated with 1 mg/ml crude LPS for 4 hr and, where indicated,
5 mM of the IAP antagonist BV6 for 1 hr. Cells were harvested and washed in
cold PBS, followed by swelling in 5 volumes of ice-cold hypotonic buffer
and mechanical disruption by passage through a 22G needle 15 times. The
cytoplasmic fraction was harvested by the centrifugation and subsequently
shifted to 30C for 0, 5, 15, or 30 min to initiate the activation of caspase-1Iand IL-1b cleavage in vitro. In cIAP2-depletion studies, supernatants were
incubated on ice with sepharose beads coupled to protein-G-adsorbed poly-
clonal antibodies to cIAP2 for 1 hr prior to incubation at 30C.
Primary BMDM Culture and Stimulation
The femurs and tibias of wild-type, Birc3/, and Casp1/ mice were flushed
with cold RPMI with a 25G needle. Themarrow plug was resuspended in RPMI
and debris removed with a 75 mm filter. The cells were spun and resuspended
in RPMI supplemented with 10% heat-inactivated FBS, 2 mM glutamine,
100 mg/ml penicillin/streptomycin, and 20% L929 conditioned media, plated
in non-tissue culture-treated dishes, and cultured at 37C in 10% CO2. Four
days later, cells were split and allowed to grow for an additional 2 days before
being plated for stimulation on day 6 of culture. For inflammasome agonist
studies, cells were primed for 4 hr with 1 mg/ml ultra-pure LPS prior to stimu-
lation with Opti-MEMminimal media (GIBCO) containing 5mMATP, 100 mg/ml
MSU, or 500 mg/ml alum. Cells were transfected with 2 mg/ml flagellin (Invivo-
gen) with DOTAP cationic lipid according to the manufacturer’s instructions.
The day of infection, a 3 mL overnight S. typhimurium (SL1344) culture was
diluted 1:10 in LB broth and grown standing to logarithmic phase (OD600 =
0.9 = 5 3 108 cfu/mL). Bacterial pellets were washed extensively with cold
PBS and diluted in Opti-MEM before infecting at MOI of 10. Supernatants
and whole cell extracts were harvested 6 hr poststimulation or 1 hr
postinfection.
RNA Extraction and Quantitative RT-PCR
Total RNA was extracted from cells with the Trizol reagent followed by chloro-
form extraction and isopropanol precipitation. 0.5 mg of the resulting RNA
was reverse-transcribed into cDNA by random hexamers and MML-V
reverse-transcriptase in a total volume of 20 ml, according to the manufac-
turers’ protocol. Quantitative PCR was performed with iTaq SYBR green
supermix and primers directed against mouse pro-IL-1b: 50-CGGCACACC
CACCCTG-30 (forward) and 50-AAACCGCTTTTCCATCTTCTTCT-30 (reverse);
ASC: 50-ACTTGTCAGGGGATGAACTC-30 (forward) and 50-TGGTACTGTCC
TTCAGTCAG-30 (reverse); NLRP3: 50-CGAGACCTCTGGGAAAAAGCT-30
(forward) and 50-GCATACCATAGAGGAATGTGATGTACA-30 (reverse) and
housekeeping gene L32: 50-GAAACTGGCGGAAACCCA-30 (forward) and 50-
GGATCTGGCCCTTGAACCTT-30 (reverse). Fold induction was calculated
over untreated levels by the delta-delta-Ct method.
Intraperitoneal Injection of Inflammasome Agonists
For neutrophil recruitment assays, age- and sex-matched wild-type, Birc2/,
Birc3/, and Casp1/ mice were injected intraperitoneally with 1 mg MSU
or 50 mg alum in 0.2 ml warm sterile PBS. Animals were euthanized by
CO2 overdose 16 hr after injection, and infiltrating cells were harvested by
peritoneal lavage with 5 mL PBS, counted and labeled for 30 min in the
dark with GR-1 antibodies coupled to FITC. The percentage of GR-1-positive
cells was determined by FACSCalibur (BD Biosciences) flow cytometry. For
IL-1b secretion studies, animals were injected as above with 1 mg MSU or
2 mg alum. The peritoneum was lavaged 4 hr postinjection with 1 ml cold
PBS and IL-1b levels measured by ELISA. Where indicated, animals were
injected intravenously with 200 ml PBS containing 1 mg/kg or 3 mg/kg BV6
or the corresponding concentration of DMSO 2 hr prior to intraperitoneal
administration of alum.
Immunoprecipitation and Pull-Down Experiments
For overexpression and coimmunoprecipitation assays, HEK293T cells
were transiently transfected with Flag-caspase-1 along with Myc-cIAP1,
Myc-cIAP2, or TRAF2 via lipofectamine 2000. At 24 hr posttransfection, cells
were washed in PBS, harvested, and lysed on ice for 30 min in B150 lysis
buffer (20 mM Tris-HCl [pH 8.0], 150 mM KCl, 10% glycerol, 5 mM MgCl2,
0.1% NP-40, and protease inhibitors) before performing three freeze-thaw
cycles. For ubiquitination assays, cells were transfected along with HA-
ubiquitin and lysed in RIPA buffer (10 mM Tris [pH 8.0], 150 mM NaCl, 1%
Nonidet P-40, 0.1% SDS, 0.5% deoxycholate, and protease inhibitor). Super-
natants were incubated for 2 hr with M2 Flag-absorbed agarose beads at 4C
followed by three washes of the beads with the lysis buffer. Immunoprecipi-
tates were eluted from the beads with Flag peptides. For endogenous
coimmunoprecipitation studies, THP-1 cell lysates were incubated withmmunity 35, 897–907, December 23, 2011 ª2011 Elsevier Inc. 905
Immunity
cIAP1 and cIAP2 Promote Caspase-1 Activitycaspase-1 antibody and protein G sepharose beads. Immunoprecipitates
were eluted by boiling in Laemmli buffer and processed for immunoblot anal-
ysis. For detection of endogenous ubiquitination BMDM from WT, Birc3/,
and Casp-1/ mice were lysed in denaturing lysis buffer (1% SDS, 50 mM
Tris [pH 7.4], 5 mM EDTA, 10 mM DTT, and protease inhibitor) then diluted
in nondenaturing buffer (20 mM Tris, 140 mM NaCl, 10% glycerol, 1% Triton
X-100, 2 mM EDTA, protease inhibitors). Lysates were immunoprecipitated
overnight with caspase-1 antibody and protein A sepharose beads. Immuno-
precipitates were eluted by boiling in Laemmli buffer and processed for
immunoblot analysis. For detection of total and K63-linked Ub, nitrocellulose
membranes were denatured by autoclaving prior to immunodetection.
GST pull-down experiments were performed in NET-N buffer (150mMNaCl,
1 mM EDTA, 50 mM Tris-HCl, 1% Triton X-100, protease inhibitor) with GST,
GST-cIAP1, and GST-cIAP2 fusion proteins produced in bacteria from
pGEX4T2 constructs.
Caspase-1 Fluorogenic Activity Assay andPropidium IodideStaining
HEK293T cells were transiently transfected with caspase-1 in combination
with pcDNA3.1, Myc-cIAP2, Myc-cIAP1, or Myc-XIAP and collected 24 hr
later. For cleavage assays, cells were lysed in CHEGG buffer (50 mM
HEPES/KOH [pH 7.0], 0.1% CHAPS, 2 mM Na-EDTA, 10% glycerol, 10 ml
1M DTT, and protease inhibitor) before sonicating for 15 s at 60% amplitude.
Lysates were incubated with 10 mM of the fluorogenic caspase-1 substrate
Ac-WEHD-AFC. The release of free AFC was monitored continuously for
1 hr (excitation 380 nm, emission 460 nm) in 1 min intervals and expressed
as arbitrary fluorescence units per minute. For PI staining, cells were washed
in PBS and resuspended in FACS buffer (2% FBS in PBS). Immediately prior
to FACS analysis, PI was added to a final concentration of 0.5 mg/ml.
Statistical Analysis
Data are represented as average ± standard error. Two-tailed Student’s t test
was used for evaluating statistical significance between groups.
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